连续血糖监测系统制造商Senseonics Holdings, Inc.（股票代码：SENS）今日盘前股价大跌7.15%，引发投资者关注。这家医疗技术公司的股价走势可能与其最新公布的融资计划有关。
根据公司公告，Senseonics于周四晚间以每股0.50美元的价格发行了1亿股普通股，总融资额达5000万美元。同时，医疗保健巨头雅培实验室（Abbott Laboratories）也参与了一项私募投资，承诺以相同价格购买最多2500万美元的股票，这将使雅培持有Senseonics约5%的股份。公司表示，这笔资金将用于支持其Eversense 365产品的持续上市，并进一步开发产品线。
尽管这笔融资为Senseonics提供了重要的资金支持，但投资者似乎对股票的潜在稀释效应表示担忧。0.50美元的发行价格低于公司近期的交易价格，这可能导致现有股东所持股份价值的下降。此外，公司终止了此前与高盛达成的550万美元场内股权销售协议，这一决定可能也影响了投资者情绪。值得注意的是，Senseonics股价已连续第五个交易日下跌，目前远低于2月中旬创下的52周高点1.40美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.